Effect of the BCL2 gene polymorphism on survival in advanced-stage non-small cell lung cancer patients who received chemotherapy

Oncology (Switzerland)

Volumn 84, Issue 4, 2013, Pages 214-218

  Masago, Katsuhiro ^a   Togashi, Yosuke ^a   Fujita, Shiro ^b   Nagai, Hiroki ^a   Sakamori, Yuichi ^a   Okuda, Chiyuki ^a   Kim, Young Hak ^a   Mishima, Michiaki ^a  

^a KYOTO UNIVERSITY   (Japan)

^b INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

Author keywords

Bcl 2; Non small cell lung cancer; Single nucleotide polymorphism

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN BCL 2;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMORADIOTHERAPY; FEMALE; GENOTYPE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SURVIVAL TIME; UNIVERSITY HOSPITAL;

EID: 84873030541     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000342854     Document Type: Article

References (19)

1. Tsujimoto Y, Croce CM: Analysis of the structure, transcripts, and protein products of Bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 1986; 83: 5214-5218.
2. Aisenberg AC, Wilkes BM, Jacobson JO: The bcl-2 gene is rearranged in many diffuse Bcell lymphomas. Blood 1988; 71: 969-972.
3. Stackhouse GB, Sesterhenn IA, Bauer JJ, Mostofi FK, Connelly RR, Srivastava SK, Moul JW: p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol 1999; 162: 2040-2045.
4. Zinkel S, Gross A, Yang E: BCL2 family in DNA damage and cell cycle control. Cell Death Differ 2006; 13: 1351-1359.
5. Faderl S, Keating MJ, Do KA, Liang SY, Kantarjian HM, O'Brien S, Garcia-Manero G, Manshouri T, Albitar M: Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia 2002; 16: 1045-1052.
6. Bilim V, Tomita Y, Kawasaki T, Katagiri A, Imai T, Takeda M, Takahashi K: Prognostic value of Bcl-2 and p53 expression in urinary tract transitional cell cancer. J Natl Cancer Inst 1996; 88: 686-688.
7. Ofner D, Riehemann K, Maier H, Riedmann B, Nehoda H, Totsch M, Bocker W, Jasani B, Schmid KW: Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Br J Cancer 1995; 72: 981-985.
8. Zhang GJ, Kimijima I, Tsuchiya A, Abe R: The role of bcl-2 expression in breast carcinomas (review). Oncol Rep 1998; 5: 1211-1216.
9. Silvestrini R, Benini E, Veneroni S, Daidone MG, Tomasic G, Squicciarini P, Salvadori B: p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 1996; 14: 1604-1610.
10. Fontanini G, Boldrini L, Vignati S, Chine S, Basolo F, Silvestri V, Lucchi M, Mussi A, Angeletti CA, Bevilacqua G: Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in nonsmall cell lung carcinoma. Eur J Cancer 1998; 34: 718-723.
11. Nuckel H, Frey UH, Bau M, Sellmann L, Stanelle J, Durig J, Jockel KH, Duhrsen U, Siffert W: Association of a novel regulatory polymorphism (-938C 1 A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. Blood 2007; 109: 290-297.
12. Lee EB, Jeon HS, Yoo SS, Choi YY, Kang HG, Cho S, Cha SI, Choi JE, Park TI, Lee BH, Park RW, Kim IS, Kang YM, Kim CH, Jheon S, Jung TH, Park JY: Polymorphisms in apoptosis-related genes and survival of patients with early-stage non-small-cell lung cancer. Ann Surg Oncol 2011; 17: 2608-2618.
13. Bachmann HS, Otterbach F, Callies R, Nuckel H, Bau M, Schmid KW, Siffert W, Kimmig R: The AA genotype of the regulatory BCL2 promoter polymorphism (938C 1 A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients. Clin Cancer Res 2007; 13: 5790-5797.
14. Lehnerdt GF, Franz P, Bankfalvi A, Grehl S, Kelava A, Nuckel H, Lang S, Schmid KW, Siffert W, Bachmann HS: The regulatory BCL2 promoter polymorphism (-938C 1 A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma. Ann Oncol 2009; 20: 1094-1099.
15. El Hindy N, Bachmann HS, Lambertz N, Adamzik M, Nuckel H, Worm K, Zhu Y, Sure U, Siffert W, Sandalcioglu IE: Association of the CC genotype of the regulatory BCL2 promoter polymorphism (-938C 1 A) with better 2-year survival in patients with glioblastoma multiforme. J Neurosurg 2011; 114: 1631-1639.
16. Knoefel LF, Werle-Schneider G, Dally H, Muller PJ, Edler L, Bartsch H, Tuengerthal S, Heussel CP, Reinmuth N, Thomas M, Risch A: Polymorphisms in the apoptotic pathway gene BCL-2 and survival in small cell lung cancer. J Thorac Oncol 2011; 6: 183-189.
17. Bachmann HS, Heukamp LC, Schmitz KJ, Hilburn CF, Kahl P, Buettner R, Nuckel H, Eisenhardt A, Rubben H, Schmid KW, Siffert W, Eggert A, Schramm A, Schulte JH: Regulatory BCL2 promoter polymorphism (-938C 1 A) is associated with adverse outcome in patients with prostate carcinoma. Int J Cancer 2011; 129: 2390-2399.
18. Hirata H, Hinoda Y, Nakajima K, Kikuno N, Suehiro Y, Tabatabai ZL, Ishii N, Dahiya R: The bcl2-938CC genotype has poor prognosis and lower survival in renal cancer. J Urol 2009; 182: 721-727.
19. Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko TK, Teo AS, Ariyaratne PN, Takahashi N, Sawada K, Fei Y, Soh S, Lee WH, Huang JW, Allen JC Jr, Woo XY, Nagarajan N, Kumar V, Thalamuthu A, Poh WT, Ang AL, Mya HT, How GF, Yang LY, Koh LP, Chowbay B, Chang CT, Nadarajan VS, Chng WJ, Than H, Lim LC, Goh YT, Zhang S, Poh D, Tan P, Seet JE, Ang MK, Chau NM, Ng QS, Tan DS, Soda M, Isobe K, Nothen MM, Wong TY, Shahab A, Ruan X, Cacheux-Rataboul V, Sung WK, Tan EH, Yatabe Y, Mano H, Soo RA, Chin TM, Lim WT, Ruan Y, Ong ST: A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 2012; 18: 521-528.